Coherus announces CCO Paul Reider resignation effective April 30, 2025

Coherus Oncology, Inc.

Paul Reider resigned as CCO and employee effective April 30, 2025, to pursue other opportunities.
Resignation follows completion of UDENYCA franchise divestiture; not due to any disagreement.
Severance includes 12 months base salary and COBRA reimbursement through Dec 31, 2026.
Vesting extended for unvested equity through Dec 31, 2026; option exercise period extended.
Reider will advise executive leadership on a part-time basis until April 30, 2026.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Paul Reider

Chief Commercial Officer

CHRS · Coherus Oncology, Inc.

Effective: 2025-04-30
Filed: April 22, 2025, 7:59 PM ET

Paul Reider notified Coherus BioSciences, Inc. (the “Company”) on April 16, 2025 of his resignation as Chief Commercial Officer and employee of the Company effective on April 30, 2025 in order to pursue other opportunities

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Reider resigned as Chief Commercial Officer at Coherus Oncology, Inc..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

Paul Reider notified Coherus BioSciences, Inc. (the “Company”) on April 16, 2025 of his resignation as Chief Commercial Officer and employee of the Company effective on April 30, 2025 in order to pursue other opportunities

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-005157

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.